Table 2 Clinical characteristics of study population at 12th month of follow-up in overall, and automatic vs. echo-guided patients
Parameters | Automatic (n 93) | Echo guided (n 98) | P value |
|---|---|---|---|
12 months follow up | |||
BMI > 30 kg/m2(%) | 7 (7.5) | 6 (6.1) | 0.622 |
Plasma glucose (mg/dl) | 173.5 ± 21.7 | 171.2 ± 20.9 | 0.171 |
HbA1c (mmol/mol) | 52.9 ± 12.1 | 52.3 ± 12.0 | 0.122 |
I NYHA class | 6 (6.4) | 2 (2.0) | 0.016* |
II NYHA class | 45 (48.4) | 21 (21.4) | 0.010* |
III NYHA class | 38 (40.9) | 66 (67.3) | 0.001* |
IV NYHA class | 4 (4.3) | 10 (10.2) | 0.021* |
QRS duration | 121.6 ± 9.6 | 122.9 ± 9.1 | 0.251 |
6MWT | 319.37 ± 26.92 | 227.92 ± 28.19 | 0.005* |
SonR values (g) | 1.09 ± 0.07 | / | / |
Echocardiographic parameters | |||
LVEF (%) | 36 ± 6 | 27 ± 5 | 0.001* |
LVEDd (mm) | 63 ± 5 | 65 ± 8 | 0.051 |
LVESd (mm) | 35 ± 4 | 38 ± 5 | 0.001* |
LVEDv (ml) | 165 ± 24 | 178 ± 41 | 0.054 |
LVESv (ml) | 109 ± 12 | 126 ± 18 | 0.001* |
Mitral insufficiency | |||
+ (%) | 50 (53.8) | 31 (31.6) | 0.040* |
+ + (%) | 38 (40.9) | 57 (58.2) | 0.004* |
+ + + (%) | 5 (5.4) | 10 (10.2) | 0.285 |
Biomarkers | |||
Lymphocytes | 7.12 ± 1.27 | 8.48 ± 1.18 | 0.001* |
Neutrophiles | 4.87 ± 1.85 | 5.69 ± 2.31 | 0.001* |
BNP (pg/ml) | 148.41 ± 16.40 | 197.26 ± 19.12 | 0.001* |
CRP (mg/L) | 7.24 ± 0.56 | 8.69 ± 0.83 | 0.036* |
IL6 (pg/ml) | 5.55 ± 0.03 | 6.31 ± 0.03 | 0.011* |
TNFα (pg/ml) | 5.35 ± 0.02 | 6.31 ± 0.02 | 0.005* |
Study outcomes | |||
CRTd responders (%) | 68 (73.1) | 58 (59.2) | 0.038* |
Hospital admission for HF worsening (%) | 12 (16.1) | 22 (22.4) | 0.030* |
Cardiac deaths (%) | 4 (4.3) | 7 (7.1) | 0.538 |
All cause of deaths (%) | 7 (7.5) | 11 (11.2) | 0.461 |